Nu Skin: New Products And Ongoing Digital Transformation Imply Undervaluation

Summary Nu Skin Enterprises, Inc. demonstrates a tested business model with long-term free cash flow generation, supported by acquisitions, new products, and digital transformation. Despite recent earnings disappointments, optimistic 2025-2026 EPS growth projections and multiple revenue catalysts suggest significant upside potential in the company’s valuation. The company’s global market expansion, cash acquisitions of LifeDNA and BeautyBio, and innovative product launches are key drivers for future net sales growth. NUS appears undervalued, trading below tangible book value per share, with conservative free cash flow forecasts indicating a fair price close to $15 per share. Lilit Amirkhanian/iStock via Getty Images Nu Skin Enterprises, Inc. (NYSE: NUS ) reports a tested business model with long-term generation of free cash flow. There are also a number of free cash flow catalysts coming from the acquisition of LifeDNA, BeautyBio, and new products such as ageLOC WellSpa iO, Nu

Click here to view original web page at seekingalpha.com